![Ab locks for improving the selectivity and safety of antibody drugs | Journal of Biomedical Science | Full Text Ab locks for improving the selectivity and safety of antibody drugs | Journal of Biomedical Science | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-020-00652-z/MediaObjects/12929_2020_652_Fig1_HTML.png)
Ab locks for improving the selectivity and safety of antibody drugs | Journal of Biomedical Science | Full Text
![The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science](https://pubs.acs.org/cms/10.1021/acscentsci.0c01448/asset/images/large/oc0c01448_0002.jpeg)
The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science
![The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice](https://www.thno.org/v10/p5815/toc.jpg)
The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice
![The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science](https://pubs.acs.org/cms/10.1021/acscentsci.0c01448/asset/images/medium/oc0c01448_0001.gif)
The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science
![PDF) Design and development of masked therapeutic antibodies to limit off-target effects Application to anti-EGFR antibodies PDF) Design and development of masked therapeutic antibodies to limit off-target effects Application to anti-EGFR antibodies](https://www.researchgate.net/profile/Ulrich-Rodeck/publication/26840719/figure/fig1/AS:601668823552015@1520460434969/antibody-prodrug-concept-a-For-proof-of-principle-eGFR-domain-III-was-fused-to-an_Q320.jpg)
PDF) Design and development of masked therapeutic antibodies to limit off-target effects Application to anti-EGFR antibodies
![PDF] A Search for the Masked Mechanism Behind IgG-Mediated Suppression of Antibody Responses | Semantic Scholar PDF] A Search for the Masked Mechanism Behind IgG-Mediated Suppression of Antibody Responses | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/98eb93918f8aac0c168c70ecee9779bb580b54ee/42-Figure3-1.png)
PDF] A Search for the Masked Mechanism Behind IgG-Mediated Suppression of Antibody Responses | Semantic Scholar
![Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies. - Abstract - Europe PMC Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3546534/bin/nihms341274f1.jpg)
Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies. - Abstract - Europe PMC
![The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science](https://pubs.acs.org/cms/10.1021/acscentsci.0c01448/asset/images/large/oc0c01448_0003.jpeg)
The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science
![Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles - Adagene Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles - Adagene](https://www.adagene.com/wp-content/uploads/2021/02/adagene-exelixis.png)
Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles - Adagene
![Ab locks for improving the selectivity and safety of antibody drugs | Journal of Biomedical Science | Full Text Ab locks for improving the selectivity and safety of antibody drugs | Journal of Biomedical Science | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-020-00652-z/MediaObjects/12929_2020_652_Fig3_HTML.png)
Ab locks for improving the selectivity and safety of antibody drugs | Journal of Biomedical Science | Full Text
![Frontiers | Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity Frontiers | Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity](https://www.frontiersin.org/files/Articles/715719/fimmu-12-715719-HTML/image_m/fimmu-12-715719-g002.jpg)
Frontiers | Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
![Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies - ScienceDirect Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1074761318303066-fx1.jpg)
Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies - ScienceDirect
![Structure and design of Probody therapeutics. (A) A Probody therapeutic... | Download Scientific Diagram Structure and design of Probody therapeutics. (A) A Probody therapeutic... | Download Scientific Diagram](https://www.researchgate.net/publication/283575362/figure/fig1/AS:312446981033984@1451504573248/Structure-and-design-of-Probody-therapeutics-A-A-Probody-therapeutic-is-a-monoclonal.png)
Structure and design of Probody therapeutics. (A) A Probody therapeutic... | Download Scientific Diagram
![Tunable modulation of antibody‐antigen interaction by protease cleavage of protein M - Kim - 2019 - Biotechnology and Bioengineering - Wiley Online Library Tunable modulation of antibody‐antigen interaction by protease cleavage of protein M - Kim - 2019 - Biotechnology and Bioengineering - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/574d6491-a996-43ab-a7fd-feb829772f56/bit27111-fig-0001-m.jpg)
Tunable modulation of antibody‐antigen interaction by protease cleavage of protein M - Kim - 2019 - Biotechnology and Bioengineering - Wiley Online Library
![Ab locks for improving the selectivity and safety of antibody drugs | Journal of Biomedical Science | Full Text Ab locks for improving the selectivity and safety of antibody drugs | Journal of Biomedical Science | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-020-00652-z/MediaObjects/12929_2020_652_Fig5_HTML.png)
Ab locks for improving the selectivity and safety of antibody drugs | Journal of Biomedical Science | Full Text
![antibody prodrug concept. (a) For proof-of-principle, eGFR domain III... | Download Scientific Diagram antibody prodrug concept. (a) For proof-of-principle, eGFR domain III... | Download Scientific Diagram](https://www.researchgate.net/publication/26840719/figure/fig1/AS:601668823552015@1520460434969/antibody-prodrug-concept-a-For-proof-of-principle-eGFR-domain-III-was-fused-to-an.png)
antibody prodrug concept. (a) For proof-of-principle, eGFR domain III... | Download Scientific Diagram
![Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains | Scientific Reports Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-017-11886-7/MediaObjects/41598_2017_11886_Fig1_HTML.jpg)
Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains | Scientific Reports
![The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science](https://pubs.acs.org/cms/10.1021/acscentsci.0c01448/asset/images/large/oc0c01448_0001.jpeg)
The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science
The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control | ACS Central Science
![A coiled-coil masking domain for selective activation of therapeutic antibodies | Nature Biotechnology A coiled-coil masking domain for selective activation of therapeutic antibodies | Nature Biotechnology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41587-019-0135-x/MediaObjects/41587_2019_135_Fig1_HTML.png)